Aidoc, the global leader in clinical AI, announced the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the company’s novel multi-triage solution
First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Raludotatug deruxtecan (R-DXd) has
Echosens, a global leader in non-invasive liver diagnostics, has shared news that the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research has
Application is based on results from SCORPIO-PEP, the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing
Medtronic plc, a leading company in healthcare technology, has received two major approvals from the FDA that expand the features of its MiniMed 780G insulin
Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Royal Philips, a global leader in
Virax Biolabs Group Limited, a biotechnology company focused on diagnosing immune responses, has entered a research agreement with Emory University to advance clinical studies for
Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung DamageInsmed Incorporated, a global biopharmaceutical
Precision BioSciences has been given Orphan Drug Designation by the U.S. Food and Drug Administration for its new treatment, PBGENE DMD, which is being developed
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment Hikma Pharmaceuticals, the multinational pharmaceutical company, announced the approval of a novel formulation of the first-of-its-kind,
The FDA has approved an updated label for Vizamyl (flutemetamol F 18 injection), including quantification which enables a more continuous and objective measure of amyloid
Precision BioSciences, a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need,
